Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31583575 | 0.88 | FUT5 (0.53) | FUT5HPGDNT5EHINT1POLB | |
| SCHEMBL21539237 | 0.88 | FUT5 (0.48) | FUT5HPGDNT5EHINT1POLB | |
| SCHEMBL18521008 | 0.86 | FUT5 (0.55) | FUT5HPGDNT5EHINT1POLB | |
| SCHEMBL30612754 | 0.85 | HPGD (0.54) | FUT5HPGDNT5EHINT1HPRT1 | |
| SCHEMBL20833471 | 0.84 | HPGD (0.51) | FUT5HPGDNT5EHINT1POLB | |
| SCHEMBL25711923 | 0.83 | HINT1 (0.50) | FUT5HPGDNT5EHINT1HPRT1 | |
| SCHEMBL18521293 | 0.83 | FUT5 (0.62) | FUT5NT5EHINT1TGM2GSK3A | |
| SCHEMBL22381693 | 0.83 | FUT5 (0.62) | FUT5NT5EHINT1TGM2GSK3A | |
| SCHEMBL18521067 | 0.82 | FUT5 (0.54) | FUT5NT5EHINT1TGM2F2 | |
| SCHEMBL6053623 | 0.82 | STING1 (0.52) | HPGDNT5EHINT1HPRT1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | FUT5 4416/4885HPGD 574/4885NT5E 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.